[
  {
    "ts": "2025-12-11T05:10:38+00:00",
    "headline": "Did Eli Lilly's (LLY) US$6 Billion Alabama Bet on Orforglipron Just Shift Its Investment Narrative?",
    "summary": "Eli Lilly and Company recently announced plans to invest more than US$6.00 billion in a new Huntsville, Alabama API facility that will produce small‑molecule and peptide medicines, including its oral GLP‑1 obesity candidate orforglipron, with construction slated to begin in 2026 and completion targeted for 2032. Alongside this large U.S. manufacturing build‑out, Lilly is advancing Jaypirca in leukemia with Phase 3 data and expanded FDA approval, underscoring how obesity and oncology...",
    "url": "https://finance.yahoo.com/news/did-eli-lillys-lly-us-051038418.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "280a4dfc-8c44-3217-a112-317e692ac122",
      "content": {
        "id": "280a4dfc-8c44-3217-a112-317e692ac122",
        "contentType": "STORY",
        "title": "Did Eli Lilly's (LLY) US$6 Billion Alabama Bet on Orforglipron Just Shift Its Investment Narrative?",
        "description": "",
        "summary": "Eli Lilly and Company recently announced plans to invest more than US$6.00 billion in a new Huntsville, Alabama API facility that will produce small‑molecule and peptide medicines, including its oral GLP‑1 obesity candidate orforglipron, with construction slated to begin in 2026 and completion targeted for 2032. Alongside this large U.S. manufacturing build‑out, Lilly is advancing Jaypirca in leukemia with Phase 3 data and expanded FDA approval, underscoring how obesity and oncology...",
        "pubDate": "2025-12-11T05:10:38Z",
        "displayTime": "2025-12-11T05:10:38Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/5eef176f2a2dc130a63fafe4bd1968dd",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/uZWvuDuy6_Wr6cKvxAFZcw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/5eef176f2a2dc130a63fafe4bd1968dd.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/g78F5NO5pySOmBHzFi6.eA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/5eef176f2a2dc130a63fafe4bd1968dd.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/did-eli-lillys-lly-us-051038418.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/did-eli-lillys-lly-us-051038418.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]